CSPC Pharmaceutical Group Ltd. said the U.S. Food and Drug Administration has approved its paclitaxel protein-bound particles for injectable suspension, rapid suspension (albumin-bound) candidate SYHX2011G1 to enter clinical trials in the United States. The approved trial will study the product for metastatic breast cancer in patients whose combination chemotherapy has failed or who relapsed within six months of adjuvant chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260302-12036786), on March 02, 2026, and is solely responsible for the information contained therein.